Bio-Rad Laboratories (NYSE:BIO – Get Free Report) and Sanuwave Health (NASDAQ:SNWV – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Profitability
This table compares Bio-Rad Laboratories and Sanuwave Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Rad Laboratories | -26.43% | 4.19% | 2.93% |
| Sanuwave Health | -17.06% | N/A | -25.20% |
Analyst Recommendations
This is a breakdown of current ratings for Bio-Rad Laboratories and Sanuwave Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Rad Laboratories | 1 | 2 | 3 | 0 | 2.33 |
| Sanuwave Health | 1 | 0 | 1 | 1 | 2.67 |
Valuation and Earnings
This table compares Bio-Rad Laboratories and Sanuwave Health”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Rad Laboratories | $2.57 billion | 3.12 | -$1.84 billion | ($24.31) | -12.22 |
| Sanuwave Health | $32.63 million | 7.00 | -$31.37 million | ($1.30) | -20.49 |
Sanuwave Health has lower revenue, but higher earnings than Bio-Rad Laboratories. Sanuwave Health is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are owned by institutional investors. 17.8% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 14.9% of Sanuwave Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Bio-Rad Laboratories has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Sanuwave Health has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
Summary
Sanuwave Health beats Bio-Rad Laboratories on 8 of the 15 factors compared between the two stocks.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
About Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
